FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

PD-Rx Pharmaceuticals Losartan Potassium Tablets Recall

Losartan Potassium Tablets, USP 100 mg, 90 Tablets bottles, Rx Only, Marketed and Packa…

PD-Rx Pharmaceuticals, Inc. · Oklahoma City, OK

Risk level
Class II
Reported by FDA
Jul 6, 2022
Recall ID
D-1163-2022
Check your lot numberHow we source this data

Summary

PD-Rx Pharmaceuticals recalled Losartan Potassium Tablets starting Jun 6, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1163-2022 on Jul 6, 2022. Reason: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits. Status: Terminated.

Why it was recalled

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Product description

Losartan Potassium Tablets, USP 100 mg, 90 Tablets bottles, Rx Only, Marketed and Packaged By: PD-Rx Pharmaceuticals, Inc. Oklahoma City, OK 73127 Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108 SIDCO Pharmaceutical Complex, Alathur, Kanchipuram-603 110, Tamilnadu, India NDC 72789-165-90 UPC 3 72789 16590 5

Lot numbers, UPCs & expiration codes

Lots: G21C26 Exp. 07/31/22; H21B96 Exp. 07/31/22; I21B39 Exp. 07/31/22; I21C44 Exp. 07/31/22; D21F35 Exp. 10/31/22; E21A66 Exp. 10/31/22; E21C72 Exp. 10/31/22; E21F01 Exp. 10/31/22; F21C15 Exp. 10/31/22; F21E19 Exp. 10/31/22; G21B14 Exp. 10/31/22; K21A61 Exp. 11/30/22; L21A45 Exp. 11/30/22

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1163-2022
Classification
Class II
Status
Terminated
Recall initiated
Jun 6, 2022
FDA report date
Jul 6, 2022
Quantity
1320 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
PD-Rx Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-1163-2022, exactly as published.

Show all FDA fields
City
Oklahoma City
State
OK
Status
Terminated
Country
United States
Event ID
90383
Address
727 N Ann Arbor Ave
Code information
Lots: G21C26 Exp. 07/31/22; H21B96 Exp. 07/31/22; I21B39 Exp. 07/31/22; I21C44 Exp. 07/31/22; D21F35 Exp. 10/31/22; E21A66 Exp. 10/31/22; E21C72 Exp. 10/31/22; E21F01 Exp. 10/31/22; F21C15 Exp. 10/31/22; F21E19 Exp. 10/31/22; G21B14 Exp. 10/31/22; K21A61 Exp. 11/30/22; L21A45 Exp. 11/30/22
Postal code
73127-5822
Report date
Jul 6, 2022
Product type
Drugs
Recall number
D-1163-2022
Classification
Class II
Recalling firm
PD-Rx Pharmaceuticals, Inc.
Product quantity
1320 bottles
Termination date
Jun 17, 2024
Reason for recall
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Voluntary / mandated
Voluntary: Firm initiated
Product description
Losartan Potassium Tablets, USP 100 mg, 90 Tablets bottles, Rx Only, Marketed and Packaged By: PD-Rx Pharmaceuticals, Inc. Oklahoma City, OK 73127 Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108 SIDCO Pharmaceutical Complex, Alathur, Kanchipuram-603 110, Tamilnadu, India NDC 72789-165-90 UPC 3 72789 16590 5
Distribution pattern
Nationwide
Recall initiation date
Jun 6, 2022
Initial firm notification
Letter
Center classification date
Jun 27, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1163-2022, published Jul 6, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls